Table: Taisho Pharmaceutical HD -2019/20 parent results
May 14 (Reuters)-
Taisho Pharmaceutical Holdings Co Ltd
PARENT-ONLY FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
Year ended Year ended Year to NEXT
Mar 31, 2020 Mar 31, 2019 Mar 31, 2021 YEAR
LATEST YEAR-AGO COMPANY COMPANY
RESULTS RESULTS FORECAST H1 FORECAST
Sales 6.01 15.62
(-61.5 pct) (+115.7 pct)
Operating 4.13 13.68
(-69.8 pct) (+141.1 pct)
Recurring 4.08 13.63
(-70.1 pct) (+143.0 pct)
Net 3.10 30.28
(-89.8 pct) (+447.2 pct)
EPS 38.81 yen 379.01 yen
EPS Diluted 38.77 yen 378.66 yen
Ann Div 110.00 yen 120.00 yen 100.00 yen
-Q2 Div 50.00 yen 50.00 yen 50.00 yen
-Q4 Div 60.00 yen 70.00 yen 50.00 yen
NOTE - Taisho Pharmaceutical Holdings Co Ltd.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4581.T
Recent news on Taisho Pharmaceutical Holdings Co
See all newsBrief: Curi RMB Capital, Kaname Capital To Request Tokyo Court To Revise Taisho Pharmaceutical's Squeeze Out Price If Taisho Disagrees With Their Demand - Nikkei
Brief: Curi RMB Capital, Kaname Capital To Request Tokyo Court To Revise Taisho Pharmaceutical's Tender Offer Price If Taisho Disagrees Their Demand - Nikkei
Activist fund Oasis says it may take legal action over Taisho's management buyout
Brief: Curi RMB Capital Opposes Taisho Pharmaceutical HD's Management Buyout
To Retire Treasury Shares Worth 3.65% Of Outstanding Stock On April 10